Literature DB >> 19464985

Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?

Maria A Curotto de Lafaille1, Juan J Lafaille.   

Abstract

Adaptive Foxp3(+)CD4(+) regulatory T (iTreg) cells develop outside the thymus under subimmunogenic antigen presentation, during chronic inflammation, and during normal homeostasis of the gut. iTreg cells are essential in mucosal immune tolerance and in the control of severe chronic allergic inflammation, and most likely are one of the main barriers to the eradication of tumors. The Foxp3(+) iTreg cell repertoire is drawn from naive conventional CD4(+) T cells, whereas natural Treg (nTreg) cells are selected by high-avidity interactions in the thymus. The full extent of differences and similarities between iTreg and nTreg cells is yet to be defined. We speculate that iTreg cell development is driven by the need to maintain a noninflammatory environment in the gut, to suppress immune responses to environmental and food allergens, and to decrease chronic inflammation, whereas nTreg cells prevent autoimmunity and raise the activation threshold for all immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464985     DOI: 10.1016/j.immuni.2009.05.002

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  448 in total

1.  T regulatory cells participate in the control of germinal centre reactions.

Authors:  Carla-Maria Alexander; Lorraine T Tygrett; Alexander W Boyden; Kristy L Wolniak; Kevin L Legge; Thomas J Waldschmidt
Journal:  Immunology       Date:  2011-06-03       Impact factor: 7.397

2.  Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice.

Authors:  Ying Wang; Geoffrey Camirand; Yan Lin; Monica Froicu; Songyan Deng; Warren D Shlomchik; Fadi G Lakkis; David M Rothstein
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

3.  Mechanisms of immune tolerance relevant to food allergy.

Authors:  Brian P Vickery; Amy M Scurlock; Stacie M Jones; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2011-01-31       Impact factor: 10.793

4.  Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.

Authors:  Matteo Vergati; Vittore Cereda; Ravi A Madan; James L Gulley; Ngar-Yee Huen; Connie J Rogers; Kenneth W Hance; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancer Immunol Immunother       Date:  2010-10-26       Impact factor: 6.968

Review 5.  Influence of dietary components on regulatory T cells.

Authors:  Shohreh Issazadeh-Navikas; Roman Teimer; Robert Bockermann
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 6.  Learning to live together: harnessing regulatory T cells to induce organ transplant tolerance.

Authors:  Andrew Y Chang; Nupur Bhattacharya
Journal:  Yale J Biol Med       Date:  2011-12

7.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

8.  Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.

Authors:  Norifumi Sawamukai; Atsushi Satake; Amanda M Schmidt; Ian T Lamborn; Priti Ojha; Yoshiya Tanaka; Taku Kambayashi
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

Review 9.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 10.  Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?

Authors:  Theresa L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2013-11-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.